nicht kleckern ..klotzen ::POZEN

POZEN Aktie WKN: 542304 ISIN: US73941U1025 buran

Buch Nasdaq RT

Zeit  Kurs  Stück  
15:32:32 5,46 $  100  
15:32:14 5,46 $  100  
15:31:09 5,44 $  100  
15:31:07 5,52 $  200  
15:31:07 5,5161 $  200  
15:30:00 5,53 $  1.200

GrB

Tickertafel:::::: 4,165 € +1,39% +0,057 €

.......alle Angaben realtime in Echtzeit und mit Kalaschnikoff

Kosmonova buran

Datum Erster Hoch Tief Schluss     Stücke Volumen
30.07.13 5,73 5,796 5,66  5,69 $ 107.589 0,61 M
GrB

SK 5,77 $ SKP -0,86 EK 5,82 $ 97.635 an die Tickertafel geschmissen und bedient ,GrB

teilgenommen haben bereits 143.959 erfolgreich bediente Stücke ..so muss das sein ..von hinten kommt die Oma mit der Sense in Opas Kämmerlein rein ..und brüllt noch laut Heinz du altes Saufschwein lasse endlich das Trinken sein ..und hol dir nen POZEN Anteilsschein

buran und danke und weitermachen

Datum Erster Hoch Tief Schluss     Stücke Volumen
06.08.13 5,87 5,90 5,61  5,77 $ 284.434 1,64 M
GrB

FFM Brief:: Preis pro Schein 4,429 € Warte 800 spread 3,99% DAX 8.258 Zählers

buran un tau

mehr als die Berge ..Berge ja auch ..aber nur an der Börse ..dann kannste zeigen wo hängt die Harke

ask Rt Kaufpreis 5,64 $ Warte 500 spread 0,18%

buran,Der Börsenbergsteiger

Du ditt macht nüscht ..guck ma ..das buran haut Dir nen schönen Nasdaq Wisch uffen Tisch:::

Datum Erster Hoch Tief Schluss     Stücke Volumen
07.08.13 5,77 5,83 5,60  5,64 $ 100.020 0,57 M

buran,Der Nasdaq Wisch Ufftischer

kanpp 80 Kilo durch den Ticker gesemmelt

ask:: Preis 5,59 $ spread 0,18%  / RT

Frankfurt 1020::: GLÜCKWUNSCH

GrB

Nasdaq Satz 08-08

Datum Erster Hoch Tief Schluss     Stücke Volumen
08.08.13 5,70 5,77 5,52  5,54 $ 108.971 0,60 M

GrB

eene meene Motze ick *piep* se inne *piep*

buran,Die Börsen POZEN

..und wir kaufen weiter

Preis:: 5,59 $ Warte 700 spread 0,36% / GrB

Preis RT 5,40 $ Warte 1.500 spread 0,19% buran und tau

die DAX Briefe:: ..Frankfurt 3,858 € ..München 3,858 € / RT / GrB

Preis pro share 5,89 $ Warte 800 spread 21,95% somit als aktuell anzusehen

...und den Germany RTK 3,836 € ,GrB

letzte Abfahrt:: 5,21 $ Schleife 300 spread 0,19% ..buran und gross Freud

95.383 getickert ..5,30 letztes ask / Preis ..somit gültig und aktuell ..buran

Sign Exclusive License Agreement for the Commercialization of PA8140/PA32540 Tablets in the U.S.22:05 04.09.13


PR Newswire

BRIDGEWATER, N.J. and CHAPEL HILL, N.J., Sept. 4, 2013

BRIDGEWATER, N.J. and CHAPEL HILL, N.J., Sept. 4, 2013 /PRNewswire/ -- Sanofi US (NYSE: SNY) and POZEN Inc. (NASDAQ: POZN) announced the signing of an exclusive license agreement for the commercialization of POZEN's proprietary, investigational, coordinated-delivery tablets combining immediate-release omeprazole, a proton pump inhibitor (PPI), and enteric-coated (EC) aspirin in a single tablet ("PA"), PA8140 and PA32540. Under the terms of the agreement, Sanofi will have exclusive rights to commercialize all PA combinations that contain 325 mg or less of enteric-coated aspirin in the United States. POZEN will receive an upfront payment of $15MM and will be eligible for pre-commercial milestone payments of up to $20MM and other future milestone payments and royalties on product sales.

(Logo: photos.prnewswire.com/prnh/20110616/NY20158LOGO)

"Sanofi has a strong heritage and expertise in the cardiovascular space, with Lovenox, Plavix, and most recently Multaq, and the PA products are an important addition to our already strong CV portfolio," said Anne Whitaker, President, North America Pharmaceuticals at Sanofi US. "The PA products have the potential to be an effective solution for the millions of patients at risk for gastric ulcers from chronic aspirin use in the prevention of secondary cardiovascular disease. We look forward to bringing this therapy to patients and healthcare providers."

Sanofi US will have responsibility for all sales, marketing, ongoing manufacturing and future development for the licensed PA products in the U.S.  POZEN will retain responsibility for obtaining approval of the New Drug Application (NDA), after which time POZEN will transfer the NDA to Sanofi US.  The NDA was submitted in March 2013 and accepted for filing in May 2013 by the U.S. Food and Drug Administration (FDA).

John R. Plachetka, Pharm.D., Chairman, President and Chief Executive Officer of POZEN Inc. said, "We are pleased to have Sanofi US commercialize PA8140 and PA32540 in the US.  We have been excited about the results of our Phase 3 clinical trials and look forward to the prospect of making this product available to cardiovascular patients at risk for gastric ulcers. Sanofi's dominant CV heritage and strong commitment to PA, make them the right partner for these products."

About PA  

POZEN has created a portfolio of investigational integrated aspirin therapies - the PA product platform. The products in the PA portfolio are being developed with the goal of significantly reducing GI ulcers and other GI complications compared to taking enteric-coated or plain aspirin alone.

The first candidates are PA32540, containing 325 mg of aspirin, and PA8140, containing 81 mg of aspirin. Both products are a coordinated-delivery tablet combining immediate-release omeprazole (40 mg), a proton pump inhibitor, layered around a pH-sensitive coating of an aspirin core. This novel, patented product is intended for oral administration once a day and an indication is being sought for use for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced gastric ulcers.

About Cardiovascular Disease

Patients with established coronary heart disease or cerebrovascular disease have a high risk of a subsequent cardiovascular event including myocardial infarction (MI), stroke and death from cardiovascular disease. For such patients, lifestyle changes and drug therapy are of proven benefit and may improve outcomes. Heart disease is the leading cause of death for both men and women in America today[i]. Coronary artery disease is the most common type of heart disease and is caused by atherosclerosis and often develops into angina pectoris and MI. This condition can lead to angina pectoris and MI and caused more than 405,000 deaths in 2008[ii]. Roughly 16.8 million people have a history of MI and/or angina[iii]. An estimated 24 million have been identified as secondary prevention patients (post-event)[iv]. It is estimated that cardiovascular disease causes one in every three deaths in the United States[v]. Every 25 seconds, someone in the United States will suffer a coronary event[vi]. About every minute, someone will die from one[vii].

About POZEN

POZEN Inc. is a small pharmaceutical company that specializes in developing novel therapeutics for unmet medical needs and licensing those products to other pharmaceutical companies for commercialization. By utilizing a unique in-source model and focusing on integrated therapies, POZEN has successfully developed and obtained FDA approval of two self-invented products in two years. Funded by these milestones/royalty streams, POZEN is creating a portfolio of cost-effective, evidence-based integrated aspirin therapies designed to enable the full power of aspirin by reducing its GI damage.

POZEN continues to seek strategic partners to help maximize the opportunities for its portfolio assets.

The Company's common stock is traded under the symbol "POZN" on The NASDAQ Global Market. For more detailed company information, including copies of this and other press releases, please visit www.pozen.com.

About Sanofi

Sanofi, an integrated global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Sanofi is the holding company of a consolidated group of subsidiaries and operates in the United States as Sanofi US, also referred to as Sanofi-aventis U.S. LLC. For more information on Sanofi US, please visit www.sanofi.us or call 1-800-981-2491.

Sanofi Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2012. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

POZEN Forward-Looking Statements

Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on current market data and research (including third party and POZEN sponsored market studies and reports), management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our inability to license our PA product candidates on terms and timing acceptable to us, our inability to file a new drug application with the FDA for our PA product candidates in the timeframe we anticipate, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval of our product candidates, including as a result of the need to conduct additional studies, or the failure to obtain such approval of our product candidates, including as a result of changes in regulatory standards or the regulatory environment during the development period of any of our product candidates; uncertainties in clinical trial results or the timing of such trials, resulting in, among other things, an extension in the period over which we recognize deferred revenue or our failure to achieve milestones that would have provided us with revenue; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products, including our dependence on AstraZeneca for the sales and marketing of VIMOVO®; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events, including those discussed herein and in our Quarterly Report on Form 10-Q for the period ended March 31, 2013. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.

Contact:








Sanofi US



Carrie Brown



(908) 981 6486



Carrie.brown@sanofi.com








POZEN Inc.



Bill Hodges
Stephanie Bonestell

Chief Financial Officer
Manager, Investor Relations and Public Relations

(919) 913 1030
(919) 913 1030

bhodges@pozen.com
sbonestell@pozen.com  


[i] American Heart Association, "Heart Disease and Stroke Statistics – 2009 Update" (2009): e32

[ii] American Heart Association, "Heart Disease and Stroke Statistics – 2012 Update" (2012): e3

[iii] American Heart Association, "Heart Disease and Stroke Statistics – 2009 Update" (2009): e175

[iv] American Heart Association, "Heart Disease and Stroke Statistics – 2010 Update" (2010): e46

[v] American Heart Association, "Heart Disease and Stroke Statistics – 2012 Update" (2012): e21

[vi] American Heart Association, "Heart Disease and Stroke Statistics – 2012 Update" (2012): e3

[vii] American Heart Association, "Heart Disease and Stroke Statistics – 2012 Update" (2012): e3

SOURCE Sanofi US


Quelle: PR Newswire

that specializes in developing novel therapeutics for unmet medical needs and licensing those products to other pharmaceutical companies for commercialization. By utilizing a unique in-source model and focusing on integrated therapies, POZEN has successfully developed and obtained FDA approval of two self-invented products in two years. Funded by these milestones/royalty streams, POZEN is creating a portfolio of cost-effective, evidence-based integrated aspirin therapies designed to enable the full power of aspirin by reducing its GI damage.

POZEN continues to seek strategic partners to help maximize the opportunities for its portfolio assets.

The Company's common stock is traded under the symbol "POZN" on The NASDAQ Global Market. For more detailed company information, including copies of this and other press releases, please visit www.pozen.com.

Datum Erster Hoch Tief Schluss     Stücke Volumen
09.09.13 5,71 5,77 5,56  5,76 $ 162.349 0,90 M

GrB

Stock Symbol: POZN
09/09/13 4:00 p.m. ET»
NASDAQ: Pozen $5.76
Change:  + 0.09 (1.59%)
Volume: 164,616

POZEN Inc., headquartered in Chapel Hill, NC, is a progressive pharmaceutical company committed to transforming medicine that transforms lives. POZEN’s unique in-source business model has been proven through our success in gaining U.S. FDA approval of two self-invented products in two years – something almost no other small pharmaceutical company has achieved. Moving forward, POZEN continues to be dedicated to addressing unmet needs and developing affordable medicines for patients and physicians.

Since our founding in 1996, POZEN has had a long, successful history of creating novel pharmacologic agents by combining existing drug therapies that result in superior patient outcomes. This approach allows for a potentially higher success rate than NCE (new chemical entity) development
www.pozen.com./

GrB

DATE TITLE  
September 04, 2013 SANOFI US and POZEN sign exclusive license agreement for the commercialization of PA8140/PA32540 tablets in the U.S.  
September 04, 2013 POZEN Announces September 5th Webcast to Discuss the PA8140/PA32540 Exclusive U.S. License Agreement



Media Inquiries:
media@pozen.com
Phone: (919) 913-1030


Fact Sheet

Executive Bios

POZEN Inc. Conference Call to Discuss the PA8140/PA32540 Exclusive U.S. License Agreement
09/05/13 at 11:00 a.m.ET Webcast - Replay
investors.pozen.com/phoenix.zhtml?c=121701&p=irol-news

POZN (Common Stock)  
Exchange NASDAQ (US Dollar)
Price $5.76
Change (%)   0.09 (1.59%)
Volume 164,616
Today's Open $5.71
Previous Close $5.67
Intraday High $5.77
Intraday Low $5.56
52 Week High $6.95
52 Week Low $4.26
Data as of 09/09/13 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote



investors.pozen.com/...ix.zhtml?c=121701&p=irol-stockquote

Date Requested 09/09/13
Last Trade $5.76
Split Adjustment Factor 1.0000:1  
Day's Low $5.56
Day's High $5.77
Open $5.71
Volume 163,542

Exchange- NASDAQ NM


NOTE: The Closing Price, Day's High, Day's Low, and Day's Volume have been adjusted to account for any stock splits and/or dividends which may have occurred for this security since the date shown above. The Actual Price is not adjusted for splits or dividends. The Split Adjustment Factor is a cumulative factor which encapsulates all splits since the date shown above.

The closing price above is not necessarily indicative of future price performance.
investors.pozen.com/...tml?c=121701&p=irol-historicalPrice

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549
_______________________________

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

09/04/13 8-K Report of unscheduled material events or corporate event Current Reports        
investors.pozen.com/phoenix.zhtml?c=121701&p=irol-sec

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): September 4, 2013

POZEN INC.

(Exact Name of Registrant as Specified in Charter)

  Delaware 000-31719§62-1657552
(State or Other Jurisdiction
of Incorporation) (Commission
File Number) (IRS Employer
Identification No.)



1414 Raleigh Road, Suite 400
Chapel Hill, North Carolina
27517
(Address of Principal Executive Offices) (Zip Code)


(919) 913-1030
(Registrant's telephone number, including area code)


Not applicable
(Former Name or Former Address, if Changed Since Last Report)

  §Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).

  §Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).

  §Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).

  §Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).



















Item 1.01 Entry into a Material Definitive Agreement

On September 3, 2013, POZEN Inc. (“POZEN”) entered into a License and Collaboration Agreement (the “ License Agreement ”) with sanofi-aventis U.S. LLC (“ Sanofi ”).  Under the License Agreement, POZEN will have the responsibility for obtaining regulatory approval and Sanofi will have responsibility for the commercialization of products containing a combination of immediate release omeprazole and 325 mg or less of delayed release aspirin, including PA32540 and PA8140, which are expected to be indicated for use for the secondary prevention of cardiovascular disease in patients at risk for aspirin-associated gastric ulcers.

Under the License Agreement, Sanofi has the exclusive right to commercialize licensed products in the United States, with POZEN retaining the right to commercialize licensed products outside the United States.  Sanofi will have responsibility for all sales, marketing and future development for the licensed products.  In addition, following approval of the New Drug Application (NDA) and completion of certain manufacturing milestones, Sanofi will have responsibility for manufacturing the licensed products for commercialization in the United States.  POZEN will retain responsibility for obtaining approval of the NDA, filed with the U.S. Food and Drug Administration (FDA) in March 2013, after which time POZEN will transfer the NDA to Sanofi.  The parties will share costs up to certain limits with respect to certain additional development activities required in order to obtain or maintain regulatory approval in the United States.   During the term of the License Agreement, POZEN may not commercialize in the United States, or license any third party to commercialize in the United States, any product combining any product indicated for treatment of gastric ulcers or gastric bleeding, or both, and 325 mg or less of aspirin.

In consideration for the rights granted to Sanofi under the License Agreement, Sanofi will pay to POZEN an upfront payment of $15 million.  POZEN is also eligible to receive pre-commercial milestone payments of $20 million and additional payments upon the achievement of specified sales milestones.  POZEN will also receive double-digit tiered royalties on sales of licensed products by Sanofi, its affiliates and its sublicensees in the United States, subject to certain adjustments specified in the License Agreement.

Sanofi will use commercially reasonable efforts to commercialize the licensed products and has agreed to specified advertising and promotional expense levels and sales details for the first two years after launch.  In the event net sales for licensed products are less than a specified amount during the third full year of commercialization, POZEN may notify Sanofi that it wishes to purchase back from Sanofi all rights to the licensed products in the United States.    In the event POZEN wishes to exercise its option, Sanofi will have the first right to buy out POZEN’s remaining interest.

The License Agreement will terminate upon the expiration of Sanofi’s royalty payment obligations, which occurs, on a licensed product-by-licensed product basis, upon the latest of (i) expiration of the last-to-expire patent covering a licensed product and (ii) a specified number of years following first commercial sale of such licensed product.  Sanofi may terminate the License Agreement at will in its entirety any time after the third anniversary of the effective date of the License Agreement.  The License Agreement may also be terminated by either party if the other party fails to cure certain material breaches under the License Agreement.   In addition, Sanofi may terminate the License Agreement under certain other specified circumstances.

The foregoing is a summary description of certain terms of the License Agreement and does not purport to be complete, and it is qualified in its entirety by reference to the full text of the License Agreement, which POZEN intends to file as exhibits to its Quarterly Report on Form 10-Q for the quarter ending September 30, 2013, with confidential terms redacted..

A copy of the press release issued in connection with the parties’ announcement of the Agreement is attached hereto as 99.1 and incorporated herein by reference.



2










SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

POZEN Inc.

By: /s/ William L. Hodges
Name: William L. Hodges
Title: Chief Financial Officer


Date:  September 4, 2013

1414 RALEIGH ROAD

SUITE 400

CHAPEL HILL NC 27517 Business Address
1414 RALEIGH ROAD

SUITE 400

CHAPEL HILL NC 27517
919-913-1030POZEN INC /NC (Filer) CIK: 0001059790 (see all company filings)
IRS No.: 621657552 | Fiscal Year End: 0919
Type: 10-K | Act: 34 | File No.: 000-31719 | Film No.: 12681216
SIC: 2834 Pharmaceutical Preparations
Assistant Director 1
www.sec.gov/cgi-bin/...er=0001140361-12-014567&xbrl_type=v

         X§Form filed by More than One Reporting Person
          §

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8) 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4) 7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock (1) 07/17/2013 P 90,000 A $ 5.25 3,356,299 D(1)


Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date
(Month/Day/Year) 7. Title and Amount of Underlying Securities
(Instr. 3 and 4) 8. Price of Derivative Security
(Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4) 11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
1. Name and Address of Reporting Person*
PAR INVESTMENT PARTNERS LP





    (Last)   (First)§(Middle)
ONE INTERNATIONAL PLACE SUITE 2401




(Street)
    BOSTON        MA§02110





    (City)   (State)§(Zip)

1. Name and Address of Reporting Person*
PAR Group, L.P.





    (Last)   (First)§(Middle)
ONE INTERNATIONAL PLACE SUITE 2401




(Street)
    BOSTON        MA§02110





    (City)   (State)§(Zip)

1. Name and Address of Reporting Person*
PAR CAPITAL MANAGEMENT INC





    (Last)   (First)§(Middle)
ONE INTERNATIONAL PLACE SUITE 2401




(Street)
    BOSTON        MA§02110





    (City)   (State)§(Zip)

Explanation of Responses:
1. These securities are held directly by PAR Investment Partners, L.P. ("PIP"). PAR Group, L.P. ("PAR Group") is the general partner of PIP. PAR Group disclaims beneficial ownership of the securities except to the extent of the pecuniary interest, if any, in such securities as a result of PAR Group's general partner interest in PIP and contingent right to a performance-based advisory fee. PAR Capital Management, Inc. ("PCM") is the general partner of PAR Group which is the general partner of PIP. PCM disclaims beneficial ownership of the securities except to the extent of the pecuniary interest, if any, in such securities as a result of PCM's general partner interest in PAR Group.
PAR Investment Partners, L.P. by PAR Group, L.P. its General Partner, by PAR Capital Management, Inc. its General Partner /s/: Steven M. Smith, Chief Operating Officer and General Counsel 07/19/2013
PAR Group, L.P. by PAR Capital Management, Inc. its General Partner /s/: Steven M. Smith, Chief Operating Officer and General 07/19/2013
PAR Capital Management, Inc. /s/: Steven M. Smith, Chief Operating Officer and General Counsel 07/19/2013
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
07/19/13 4 Statement of changes in beneficial ownership of securities 3,4,5        
investors.pozen.com/...=irol-sec&control_selectgroup=3,4,5

Analysts
Firm Name Analyst Name Phone
Ascendiant Capital Markets, LCC Keay  Nakae, CFA  (949) 259-4933
ROTH Capital Partners Robert Hazlett (646) 358-1912
Zacks Equity Research Jason Napodano (312) 265-9421



Estimates
First Call Mean Estimates
Fiscal Year Ending: Dec - Last Changed: 09/06/13
YR Ending Q1
Mar  Q2
Jun  Q3
Sep  Q4
Dec  FISC YR Annual NUM Brokers (FISC) CAL YR Annual NUM Brokers (CAL)
2017             1.57  1  1.57  1  
2016             0.80  1  0.80  1  
2015             0.34  1  0.34  1  
2014  -0.04 0.29  0.17  -0.15  0.41  2  0.41  2  
2013  -0.19A -0.13A -0.09  0.55  0.14  2  0.14  2  
2012  -0.28A -0.17A -0.19A -0.20A -0.84  5  -0.84  0  
2011  -0.19A -0.21A -0.24A 2.04A 1.40  3  1.40  0  
2010  -0.10A 0.53A -0.29A 0.61A 0.76  6  0.76  5  
2009  -0.12A -0.14A 0.22A -0.19A -0.23  6  -0.23  6  
2008  -0.25A 0.43A -0.26A -0.14A -0.20  5  -0.20  5  
2007  -0.07A -0.13A 0.48A -0.14A 0.15  10  0.15  10  
2006  -0.22A -0.29A -0.14A -0.01A -0.66  10  -0.66  10  
2005  -0.19A -0.14A -0.16A 0.54A 0.07  5    

Mean Recommendation: 1.67
Mean Future 5 Year Growth Rate: 30
investors.pozen.com/...zhtml?c=121701&p=irol-earningsTable

::::::: 5,90 $ +0,68% +0,04 $ In Euro: 4,3758 € | Nasdaq ,GrB

Datum Erster Hoch Tief Schluss     Stücke Volumen
09.10.13 5,64 5,66 5,51  5,58 $ 159.557 0,84 M

GrB

Frankfurt 4,205 € München 4,205 € Nasdaq 7,02 $ buran und MfG und tau

RTK 5,70  $ RTP +2,15 EK 5,58 $  last 100 full 67.013 peak 5,755 ,GrB

Preis 5,70 $ Schleife 300 spread 0,18%  

:::::::::::::::::::::::: 4,572 € +3,67% +0,162 € ,GrB

Datum Erster Hoch Tief Schluss     Stücke Volumen
24.10.13 6,25 6,48 6,1998  6,44 $ 822.889 5,21 M

GrB

Datum Erster Hoch Tief Schluss     Stücke Volumen
  13.11.13      5,71      5,84§5,6401 5,81 $ 148.248 0,84 M

GrB

Datum Erster Hoch Tief Schluss     Stücke Volumen
19.11.13 6,27 7,00 6,05   6,68 $ 1.812.292 11,7 M

GrB

Datum Erster Hoch Tief Schluss     Stücke Volumen
21.11.13 6,80 6,81 6,65   6,80 $ 580.288 3,66 M

GrB

Zeit   Kurs Stück
10:29:31 6,017 € 500
08:03:19 5,943 € 1.500
__________________
GRATULATION

RTK 7,8801  $ RTP -0,13 EK 7,89 $ last shares 193 full RT 97.150 peak 7,90 buran und MfG und danke und weitermachen

Zeit    Kurs Stück
  19:52:36§6,224 € 144
_________________
GRATULATION§

SK 8,76  $ SKP +5,54 EK 8,30 $ last shares 253 full 813.682 peak 8,86

buran und MfG und danke und sowieso und überhaupt und HOLLA DIE WALDFEE

Zeit      Kurs Stück
  12:43:23§6,488 € 70
________________
GRATULATION

RTK 8,89  $ RTP +1,48 EK 8,76 $ last shares 190 full realtime 47.574 peak 8,89

buran und MfG und danke und weiter immer weiter immer schneller wie PROPELLER

Datum Erster Hoch Tief Schluss     Stücke Volumen
  11.12.13     6,241     6,488§6,241 6,488 € 70 454

GrB

Datum Erster Hoch Tief Schluss     Stücke Volumen
  11.12.13      8,77      9,12§8,455 8,74 $ 778.196 6,66 M

GrB

Datum Erster Hoch Tief Schluss     Stücke Volumen
  03.01.14      8,30      8,32§7,95 8,14 $ 430.725 3,42 M

GrB

Datum Erster Hoch Tief Schluss     Stücke Volumen
  10.01.14     5,899     6,141§5,899 6,141 € 1.400 8.596

GrB

Datum Erster Hoch Tief Schluss     Stücke Volumen
  10.01.14      8,22      8,25§8,13 8,24 $ 248.139 1,97 M

GrB

Datum Erster Hoch Tief Schluss     Stücke Volumen
  17.01.14      8,64      8,91§8,64 8,80 $ 259.360 2,21 M

GrB

Datum Erster Hoch Tief Schluss     Stücke Volumen
  20.01.14      6,37      6,37§6,37 6,37 € * 0 0
  17.01.14     6,209     6,448§6,209 6,448 € 50 322

GrB

RTK 6,37 € RTP -1,21 Pott +55,06% buran und MfG und schüddelbööööön

Bucheinsicht http://www.ariva.de/pozen-aktie/times_and_sales?boerse_id=40 GrB

Preis pro share 8,18 $ Schleife 100 spread 0,37% buran und MfG und FREIHEIT FÜR NELSON MANDELA ..::hopshopshopshopshopshops

Datum Erster Hoch Tief Schluss     Stücke Volumen
  09.04.14      8,61    8,8065§8,60 8,73 $ 503.031 4,38 M

GrB

http://www.ariva.de/news/...-Supplier-of-an-Active-Ingredient-5015349 GrB

http://www.ariva.de/news/...lf-of-Investors-of-Pozen-Inc-POZN-5019943 GrB

2014 Results
07:49 02.05.14

CHAPEL HILL, N.C. --(BUSINESS WIRE)--

POZEN Inc. (NASDAQ: POZN),a pharmaceutical company committed to transforming medicine that transforms lives, announced today that it plans to release first quarter 2014 results on May 8, 2014, before the market opens.

The announcement will be followed by a live webcast at 11:00 a.m. (ET) with a discussion by POZEN management of the earnings and business results. The webcast can be accessed on POZEN’s website at www.pozen.com and will be archived and available for replay. The first quarter 2014 earnings release will be accessible in the Media section of POZEN’s website.

About POZEN

POZEN Inc. is a small pharmaceutical company that specializes in developing novel therapeutics for unmet medical needs and licensing those products to other pharmaceutical companies for commercialization. By utilizing a unique in-source model and focusing on integrated therapies, POZEN has successfully developed and obtained FDA approval of two self-invented products in two years. Funded by these milestones/royalty streams, POZEN is creating a portfolio of cost-effective, evidence-based integrated aspirin therapies designed to enable the full power of aspirin by reducing its GI damage.

POZEN is currently seeking ex-U.S. strategic partners to help maximize the opportunities for its portfolio assets.

The Company's common stock is traded under the symbol “POZN” on The NASDAQ Global Market. For more detailed company information, including copies of this and other press releases, please visit www.pozen.com.



(c)Business Wire. All of the news releases contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Business Wire's members, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.http://www.ariva.de/news/...ast-of-First-Quarter-2014-Results-5021354

POZEN Inc. is a small pharmaceutical company that specializes in developing novel therapeutics for unmet medical needs and licensing those products to other pharmaceutical companies for commercialization. By utilizing a unique in-source model and focusing on integrated therapies, POZEN has successfully developed and obtained FDA approval of two self-invented products. Funded by these milestones/royalty streams, POZEN has created a portfolio of cost-effective, evidence-based integrated aspirin therapies designed to enable the full power of aspirin by reducing its GI damage.

POZEN is currently seeking strategic partners to help maximize the opportunities for its portfolio assets.

The Company's common stock is traded under the symbol “POZN” on The NASDAQ Global Market. For more detailed company information, including copies of this and other press releases, please visit www.pozen.com.

About PA

POZEN has created a portfolio of investigational integrated aspirin therapies - the PA product platform. The products in the PA portfolio are being developed with the goal of significantly reducing GI ulcers and other GI complications compared to taking enteric-coated or plain aspirin alone.

The first candidates are PA8140, containing 81 mg of aspirin, and PA32540, containing 325 mg of aspirin. Both products are a coordinated-delivery tablet combining immediate-release omeprazole (40 mg), a proton pump inhibitor, layered around a pH-sensitive coating of an aspirin core. This novel, patented product is intended for oral administration once a day and an indication is being sought for use for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced gastric ulcers.

Proposed PA Indications and Usage (Pending FDA Review and Approval)

PA8140/PA32540 Tablets contain 81 mg or 325 mg delayed release aspirin and 40 mg immediate-release omeprazole and are indicated for patients who require aspirin (1) to reduce the combined risk of death and nonfatal stroke in patients who have had ischemic stroke or transient ischemia of the brain due to fibrin platelet emboli, (2) to reduce the combined risk of death and nonfatal MI in patients with a previous MI or unstable angina pectoris, (3) to reduce the combined risk of MI and sudden death in patients with chronic stable angina pectoris, (4) in patients who have undergone revascularization procedures (CABG, PTCA) when there is a pre-existing condition for which aspirin is already indicated, and to decrease the risk of developing gastric ulcers in patients at risk for developing aspirin-associated gastric ulcers.

Controlled studies with PA8140/PA32540 Tablets do not extend beyond 6 months.

Forward-Looking Statements

Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results, our ability to return value to our stockholders, including any cash distributions, and our future prospects could differ materially from those contained in the forward-looking statements, which are based on current market data and research (including third party and POZEN sponsored market studies and reports), management’s current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our inability to further license our PA product candidates on terms and timing acceptable to us, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval of our product candidates, including as a result of the need to conduct additional studies or due to issues with third-party manufacturers, or the failure to obtain such approval of our product candidates for all expected indications, including as a result of changes in regulatory standards or the regulatory environment during the development period of any of our product candidates; uncertainties in clinical trial results or the timing of such trials, resulting in, among other things, an extension in the period over which we recognize deferred revenue or our failure to achieve milestones that would have provided us with revenue; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products, including our dependence on AstraZeneca and Horizon for the sales and marketing of VIMOVO®, our dependence on Sanofi US for the sales and marketing of PA8140/PA32540 in the United States, if approved, and our dependence on Patheon for the manufacture of PA8140/PA32540; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events, including those discussed herein and in our Quarterly Report on Form 10-Q for the period ended March 31, 2014. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.



(c)Business Wire. All of the news releases contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Business Wire's members, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.http://www.ariva.de/news/POZEN-Resubmits-PA8140-PA32540-NDA-5087927

The Company's common stock is traded under the symbol “POZN” on The NASDAQ Global Market. For more detailed company information, including copies of this and other press releases, please visit www.pozen.com.



(c)Business Wire. All of the news releases contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Business Wire's members, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.http://www.ariva.de/news/...st-of-Second-Quarter-2014-Results-5111371

http://www.ariva.de/news/...n-Acquired-by-Pernix-Therapeutics-5139895 GrB

Datum Erster Hoch Tief Schluss     Stücke Volumen
  24.10.14      8,78      8,94§8,69 8,75 $ 256.474 2,25 M

GrB

buran: nur ein börsenboard geführt von www.bundesbank.de 21:18 #1
achte er einfach auf die links
Mit freundlichen Grüssen Mario Meierhof 39517 Lüderitz Gartenstrasse 6
mariomeierhof@web.de
Tel.:039361/96548 Atelier Meierhof 039361/51273 Kuhle
gez MARIO alias buran http://www.ariva.de/…/nur-ein-boersenboard-gefuehrt-von-www…

Deutsche Bundesbank - Startseite
Die Deutsche Bundesbank ist die Zentralbank der Bundesrepublik Deutschland. Zentrales Geschäftsfeld ist die Geldpolitik des Eurosystems.
BUNDESBANK.DE
https://www.facebook.com/mario.meierhof

buran: auch ich war im Erziehungsheim lange eine Ewigkeit 228.10.14 20:01 #1
Mario Meierhof
29. September um 21:38 ·
buran: nur ein börsenboard geführt von www.bundesbank.de 21:18 #1
achte er einfach auf die links
Mit freundlichen Grüssen Mario Meierhof 39517 Lüderitz Gartenstrasse 6
mariomeierhof@web.de
Tel.:039361/96548 Atelier Meierhof 039361/51273 Kuhle
gez MARIO alias buran http://www.ariva.de/…/nur-ein-boersenboard-gefuehrt-von-www…

Deutsche Bundesbank - Startseite
Die Deutsche Bundesbank ist die Zentralbank der Bundesrepublik Deutschland. Zentrales Geschäftsfeld ist die Geldpolitik des Eurosystems.
BUNDESBANK.DE
https://www.facebook.com/mario.meierhof
http://www.ariva.de/forum/...rziehungsheim-lange-eine-Ewigkeit-510117

buran: Kontakt   01.10.14 21:33 #1 Inhalt
Haben Sie Fragen oder Anmerkungen?
Dann nutzen Sie unser Kontaktformular, um uns eine Nachricht zukommen zu lassen.
Als Medienvertreter nutzen Sie bitte die Seite cvd.bundesregierung.de.
Felder mit einem * sind Pflichtfelder und müssen ausgefüllt werden.
Selbstverständlich beachten wir die Vorschriften des Datenschutzes.
Hier geht es zur Datenschutzerklärung.

Betreff * Hallo ,vielleicht sowas mal unterbinden wäre nett


Ihre Anregungen und Fragen (max. 10.000 Zeichen) *noch 9663 Zeichen nur ein börsenboard geführt von www.bundesbank.de
achte er einfach auf die links

Mit freundlichen Grüssen Mario Meierhof 39517 Lüderitz Gartenstrasse 6
mariomeierhof@web.de
Tel.:039361/96548 Atelier Meierhof 039361/51273 Kuhle

gez MARIO alias buran http://www.ariva.de/forum/...rd-gefuehrt-von-www-bundesbank-de-508523


Vor- und Zuname * Mario Meierhof

E-Mail *mariomeierhof@web.de


Straße und Hausnummer Gartenstrasse 6

Postleitzahl 39517

Ort Lüderitz

* Pflichtangabe
https://www.bundesregierung.de/Webs/Breg/DE/.../kontaktform_node.html

Mit freundlichen Grüssen Mario Meierhof alias buran
http://www.ariva.de/forum/Kontakt-508620?new_pnr=18779196#bottom

http://www.ariva.de/news/...-S-Partnership-for-PA8140-PA32540-5228196 GrB

http://www.ariva.de/news/...lete-Response-Letter-from-The-FDA-5242101 GrB

of VIMOVO® Related Patent by the United States Patent and Trademark Office
22:10 04.02.15

CHAPEL HILL, N.C. --(BUSINESS WIRE)-- http://www.ariva.de/news/...tates-Patent-and-Trademark-Office-5276283

company committed to transforming medicine that transforms lives, today announced the issuance of a patent by the United States Patent and Trademark Office (USPTO) entitled “Method for Treating a Patient at Risk for Developing an NSAID-associated Ulcer” that relates to VIMOVO® (naproxen/esomeprazole magnesium) delayed release tablets in patients taking low dose aspirin. The patent expires in October 2031. http://www.ariva.de/news/...tates-Patent-and-Trademark-Office-5276283

“This newly issued patent provides additional claims to the VIMOVO patent estate,” stated John R. Plachetka, Chairman, President and Chief Executive Officer. “This patent further demonstrates the continued pattern of innovation by POZEN, which has resulted in 17 issued U.S. Patents and many related foreign patents.” http://www.ariva.de/news/...tates-Patent-and-Trademark-Office-5276283

“This newly issued patent provides additional claims to the VIMOVO patent estate,” stated John R. Plachetka, Chairman, President and Chief Executive Officer. “This patent further demonstrates the continued pattern of innovation by POZEN, which has resulted in 17 issued U.S. Patents and many related foreign patents.” http://www.ariva.de/news/...tates-Patent-and-Trademark-Office-5276283

..besser Inglisch with the Satzstellung ..nä ..::hopshops

..kommt man ja reinewech und durchenander ..ey

zum Orbit Rasthof Steigerwald und seine Rumpelkammer ..geile Kellnerin Du ..datt Willichen nä ..hee hee ..unddd SDROWJE

buran

8,945,621 on February 3, 2015. Horizon Pharma plc (NASDAQ: HZNP), which holds the U.S. NDA for VIMOVO, and POZEN plan to list the U.S. patent in the U.S. Food and Drug Administration's Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book. This will be the eleventh U.S. patent to be listed in the Orange Book for VIMOVO. http://www.ariva.de/news/...tates-Patent-and-Trademark-Office-5276283

buran

..yöah

Fourth Quarter and Year End 2014 Results
13:30 04.03.15

CHAPEL HILL, N.C. --(BUSINESS WIRE)--

POZEN Inc. (NASDAQ: POZN),a pharmaceutical company committed to transforming medicine that transforms lives, announced today that it plans to release fourth quarter and year end 2014 results on March 9, 2015, before the market opens. http://www.ariva.de/news/...Quarter-and-Year-End-2014-Results-5301074

webcast at 11:00 a.m. (ET) with a discussion by POZEN management of the earnings and business results. The webcast can be accessed on POZEN’s website at www.pozen.com and will be archived and available for replay. The fourth quarter and year end 2014 earnings release will be accessible in the Media section of POZEN’s website. http://www.ariva.de/news/...Quarter-and-Year-End-2014-Results-5301074

..muha

buran & MARIO www.facebook.com/mario.meierhof/

Results
12:30 09.03.15

CHAPEL HILL, N.C. --(BUSINESS WIRE)--

POZEN Inc. (NASDAQ: POZN),a pharmaceutical company committed to transforming medicine that transforms lives, today announced results for the fourth quarter and year ended December 31, 2014. http://www.ariva.de/news/...Quarter-and-Year-End-2014-Results-5304833

Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results, our ability to return value to our stockholders, including any cash distributions, and our future prospects could differ materially from those contained in the forward-looking statements, which are based on current market data and research (including third party and POZEN sponsored market studies and reports), management’s current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our inability to further license our YOSPRALA product candidates on terms and timing acceptable to us, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval of our product candidates, including as a result of the need to conduct additional studies or due to issues with third-party manufacturers, or the failure to obtain such approval of our product candidates for all expected indications, including as a result of changes in regulatory standards or the regulatory environment during the development period of any of our product candidates; uncertainties in clinical trial results or the timing of such trials, resulting in, among other things, an extension in the period over which we recognize deferred revenue or our failure to achieve milestones that would have provided us with revenue; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products, including our dependence on AstraZeneca and Horizon for the sales and marketing of VIMOVO®, our dependence on Patheon for the manufacture of YOSPRALA 81/40 and YOSPRALA 325/40; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events, including those discussed herein and in our Quarterly Report on Form 10-Q for the period ended September 30, 2014. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements. http://www.ariva.de/news/...Quarter-and-Year-End-2014-Results-5304833

First Quarter 2015 Results
22:05 04.05.15

CHAPEL HILL, N.C. --(BUSINESS WIRE)--

POZEN Inc. (NASDAQ: POZN),a pharmaceutical company committed to transforming medicine that transforms lives, announced today that it plans to release first quarter 2015 results on May 8, 2015, before the market opens.

The announcement will be followed by a live webcast at 10:00 a.m. (ET) with a discussion by POZEN management of the earnings and business results. The webcast can be accessed on POZEN’s website at www.pozen.com and will be archived and available for replay. The first quarter 2015 earnings release will be accessible in the Media section of POZEN’s website. http://www.ariva.de/news/...ast-of-First-Quarter-2015-Results-5356175

13:40 08.05.15

CHAPEL HILL, N.C. --(BUSINESS WIRE)--

POZEN Inc. (NASDAQ: POZN),a pharmaceutical company committed to transforming medicine that transforms lives, today announced results for the first quarter ended March 31, 2015. http://www.ariva.de/news/...eports-First-Quarter-2015-Results-5361986

Q1 2015 was the fourth consecutive quarter of positive cash flow.
Royalty revenue for Q1 2015 was $4.4 million compared to $4.5 million for Q1 2014.
Q1 2015 expenses decreased by $0.4 million to $4.2 million compared to Q1 2014.
In Q1 2015, POZEN announced the issuance of a patent by the United States Patent and Trademark Office (USPTO) entitled “Method for Treating a Patient at Risk for Developing an NSAID-associated Ulcer” that relates to VIMOVO® (naproxen/esomeprazole magnesium) delayed release tablets in patients taking low dose aspirin. The patent expires in October 2031.
http://www.ariva.de/news/...eports-First-Quarter-2015-Results-5361986

The Company received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) on April 25, 2014 and on December 16, 2014 stating that satisfactory resolution of inspection deficiencies found during an inspection of the active ingredient supplier’s manufacturing facility in April 2014 was required before the Company’s New Drug Application (NDA) for YOSPRALA 81/40 or YOSPRALA 325/40 could be approved. There were no clinical or safety deficiencies noted with respect to either YOSPRALA 81/40 or YOSPRALA 325/40 and no other deficiencies were noted in either CRL. Final agreement on the draft product labeling is also pending. http://www.ariva.de/news/...eports-First-Quarter-2015-Results-5361986

For the first quarter of 2015, POZEN reported total revenue of $4.4 million, resulting from VIMOVO royalty. For the first quarter of 2014, the Company reported total revenue of $7.5 million, resulting from $4.5 million of VIMOVO royalty and $3.0 million of amortization of the upfront fee for licensing of YOSPRALA. http://www.ariva.de/news/...eports-First-Quarter-2015-Results-5361986

At March 31, 2015, cash and cash equivalents totaled $43.9 million, up $3.3 million from December 31, 2014. Accounts receivable totaled $4.4 million. http://www.ariva.de/news/...eports-First-Quarter-2015-Results-5361986

POZEN will host a webcast to present first quarter 2015 results and management’s outlook on Friday, May 8, 2015 at 10:00 a.m. (EDT). The webcast can be accessed live and will be available for replay at www.pozen.com. http://www.ariva.de/news/...eports-First-Quarter-2015-Results-5361986

Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results, our ability to return value to our stockholders, including any cash distributions, and our future prospects could differ materially from those contained in the forward-looking statements, which are based on current market data and research (including third party and POZEN sponsored market studies and reports), management’s current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our inability to further license our YOSPRALA product candidates on terms and timing acceptable to us, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval of our product candidates, including as a result of the need to conduct additional studies or due to issues with third-party manufacturers, or the failure to obtain such approval of our product candidates for all expected indications, including as a result of changes in regulatory standards or the regulatory environment during the development period of any of our product candidates; uncertainties in clinical trial results or the timing of such trials, resulting in, among other things, an extension in the period over which we recognize deferred revenue or our failure to achieve milestones that would have provided us with revenue; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products, including our dependence on AstraZeneca and Horizon for the sales and marketing of VIMOVO®, our dependence on Patheon for the manufacture of YOSPRALA 81/40 and YOSPRALA 325/40; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events, including those discussed herein and in our Annual Report on Form 10-K for the period ended December 31, 2014. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements. http://www.ariva.de/news/...eports-First-Quarter-2015-Results-5361986

POZEN Inc. is a small pharmaceutical company that specializes in developing novel therapeutics for unmet medical needs and licensing those products to other pharmaceutical companies for commercialization. By utilizing a unique in-source model and focusing on integrated therapies, POZEN has successfully developed and obtained FDA approval of two self-invented products. Funded by these milestones/royalty streams, POZEN has created a portfolio of cost-effective, evidence-based integrated aspirin therapies designed to enable the full power of aspirin by reducing its GI damage. http://www.ariva.de/news/...eports-First-Quarter-2015-Results-5361986

symbol “POZN” on The NASDAQ Global Market. For more detailed company information, including copies of this and other press releases, please visit www.pozen.com. http://www.ariva.de/news/...eports-First-Quarter-2015-Results-5361986

buran & MARIO https://www.facebook.com/mario.meierhof/

POZEN Announces Retirement of Founder, Chairman and CEO Dr. John R. Plachetka; Adrian Adams Named as CEO
13:05 01.06.15

CHAPEL HILL, N.C. --(BUSINESS WIRE)--

POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to developing medicine that transforms lives, today announced that John R. Plachetka, Pharm.D., its founder, Chairman, Chief Executive Officer and President is retiring, effective immediately. Dr. Plachetka has also resigned from the Board of Directors of POZEN and has withdrawn as a nominee for election as a director at the 2015 Annual Meeting of Stockholders. http://www.ariva.de/news/...achetka-Adrian-Adams-Named-as-CEO-5382300

an Intangible Property Transfer Arrangement
13:35 02.06.15

CHAPEL HILL, N.C. --(BUSINESS WIRE)--

POZEN Inc. (NASDAQ: POZN),a pharmaceutical company committed to developing medicine that transforms lives, today announced that it has formed POZEN Limited, a wholly owned Irish subsidiary and has entered in an Intangible Property Transfer Arrangement between POZEN Inc. and POZEN Limited. http://www.ariva.de/news/...ble-Property-Transfer-Arrangement-5383649

POZEN Announces Strategic Acquisition of Tribute and Growth Capital Commitment from Leading Healthcare Sponsors
16:50 08.06.15

CHAPEL HILL, N.C. & MILTON, Ontario --(BUSINESS WIRE)--

POZEN Inc. (“POZEN”) (NASDAQ: POZN), a pharmaceutical company committed to developing medicine that transforms lives, today announced the acquisition of Tribute Pharmaceuticals Canada Inc. (“Tribute”) (TSXV:TRX or OTCQX:TBUFF), a Canadian specialty pharmaceutical company, in a transaction valued at approximately US$146 million. Upon completion of the acquisition, which is expected to occur in the fourth quarter of 2015, the combined company will be named Aralez Pharmaceuticals plc (“Aralez” or the “Company”) and domiciled in Ireland. Upon closing, Aralez is expected to trade on NASDAQ and TSX. http://www.ariva.de/news/...-from-Leading-Healthcare-Sponsors-5388586

13:35 22.06.15

CHAPEL HILL, N.C. --(BUSINESS WIRE)--

POZEN Inc. (“POZEN”) (NASDAQ:POZN), a pharmaceutical company committed to developing medicine that transforms lives, today announced appointments to its Executive Leadership Team led by newly appointed Chief Executive Officer, Adrian Adams. http://www.ariva.de/news/...nnounces-Key-Leadership-Additions-5400716

of Finance
13:05 27.07.15

CHAPEL HILL, N.C. --(BUSINESS WIRE)--

POZEN Inc. (“POZEN”) (NASDAQ:POZN), a pharmaceutical company committed to developing medicine that transforms lives, today announced that Scott Charles will be appointed Senior Vice President of Finance of POZEN, effective July 27th, with the intention of becoming Chief Financial Officer of Aralez Pharmaceuticals plc. upon completion of the pending merger of POZEN with Tribute Pharmaceuticals Canada Inc. Mr. Charles will report to Adrian Adams, Chief Executive Officer of POZEN, and will be responsible for all financial activities related to the integration of Tribute Pharmaceuticals upon its anticipated merger with POZEN and with respect to the implementation of all systems necessary for the planned transformation of POZEN and ultimately Aralez Pharmaceuticals into a commercial specialty pharmaceuticals company. He will also play a critical role on the leadership team. http://www.ariva.de/news/...-Senior-Vice-President-of-Finance-5435596

POZEN Announces August 10th Webcast of Second Quarter 2015 Results
13:35 27.07.15

CHAPEL HILL, N.C. --(BUSINESS WIRE)--

POZEN Inc. (NASDAQ: POZN) announced today that it plans to release second quarter 2015 results on August 10, 2015, before the market opens.

The announcement will be followed by a live webcast at 2:00 p.m. (EDT) with a discussion by POZEN management of the earnings and business results. The webcast can be accessed on POZEN’s website at www.pozen.com and will be archived and available for replay. The second quarter 2015 earnings release will be accessible in the Media section of POZEN’s website. http://www.ariva.de/news/...st-of-Second-Quarter-2015-Results-5435638

POZEN Reports Second Quarter 2015 Results
13:05 10.08.15

CHAPEL HILL, N.C. --(BUSINESS WIRE)--

POZEN Inc. (NASDAQ:POZN),today announced results for the second quarter ended June 30, 2015. The Company highlighted important corporate, commercial, and regulatory updates from the quarter.

Total revenues resulting from VIMOVO® royalties for the three month period ended June 30, 2015, were $5.2 million, compared to total revenues of $7.4 million in the second quarter of 2014 that included $5.4 million of royalties and $2.0 million of amortization of the upfront fee for licensing of YOSPRALA, representing a decrease of thirty percent. Total revenues for the second quarter of 2015 increased 18% from the first quarter of 2015, reflecting royalty increases in both US and non-US markets. http://www.ariva.de/news/...ports-Second-Quarter-2015-Results-5452637

Datum Erster Hoch Tief Schluss     Stücke Volumen
  24.08.15      8,00      8,61§7,89 8,09 $ 867.007 7,11 M

GrB

Transaction with Tribute Pharmaceuticals Canada Inc.
15:05 02.02.16

PR Newswire

CHAPEL HILL, N.C., Feb. 2, 2016

-Transaction Expected to Close on or About February 5, 2016-

CHAPEL HILL, N.C., Feb. 2, 2016 /PRNewswire/ -- POZEN Inc. ("POZEN") (NASDAQ: POZN), a specialty pharmaceutical company, today announced that its stockholders approved the Agreement and Plan of Merger and Arrangement (the "Merger Agreement") with Tribute Pharmaceuticals Canada Inc. ("Tribute") and the carrying out of the transactions contained therein. Upon closing of the transaction, the POZEN and Tribute businesses will operate as subsidiaries of Aralez Pharmaceuticals Inc. ("Aralez"), a company domiciled in Canada.

The Merger Agreement was also adopted by the Tribute shareholders on February 1, 2016. The proposed transaction remains subject to certain conditions and approvals, including approval of the Ontario Superior Court of Justice, listing of Aralez shares and customary closing conditions, and is expected to occur promptly following satisfaction of all conditions. Aralez will be listed on the NASDAQ stock exchange under the ticker symbol "ARLZ" and is expected to begin trading on or about February 8, 2016, and will be listed on the Toronto Stock Exchange ("TSX") under the ticker symbol "ARZ" and is expected to begin trading on on or about February 10, 2016, assuming closing on February 5, 2016. http://www.ariva.de/news/...ribute-Pharmaceuticals-Canada-Inc-5634621

POZEN And Tribute Combine To Create Aralez Pharmaceuticals Inc.
19:20 05.02.16

PR Newswire

MILTON, Ontario, Feb. 5, 2016

-Transformative Transaction Creates Premier Specialty Pharma Company with a Broad Product Portfolio-

-Canadian Domicile Provides Compelling Platform for Growth with Competitive Structure-

-US$350 Million Capital Commitment from Deerfield-Led Syndicate-

MILTON, Ontario, Feb. 5, 2016 /PRNewswire/ -- Aralez Pharmaceuticals Inc. ("Aralez") today announced the completion of the business combination of POZEN Inc. ("POZEN") and Tribute Pharmaceuticals Canada Inc. ("Tribute") following approval of the transaction by stockholders of POZEN and shareholders of Tribute. The combined company will operate under Aralez Pharmaceuticals Inc. ("Aralez"), a global specialty pharmaceutical company with operations in Canada, Ireland and the United States. Under the terms of the Agreement and Plan of Merger and Arrangement, each share of POZEN common stock has been converted into the right to receive one Aralez common share and each common share of Tribute (other than dissenting shares) has been exchanged for 0.1455 Aralez common shares. http://www.ariva.de/news/...Create-Aralez-Pharmaceuticals-Inc-5639523

http://www.ariva.de/pozen-aktie/chart GrB

kein aktueller Kurs verfügbar ,GrB

kein aktueller Kurs verfügbar ,GrB

hier in bayern auch kein kurs
wie schauts im norden aus?

..klick und denn navigieren ..Route diagonal ..nein ..einfach plan rüber ..Einsicht auf Ende rechter Hand http://www.ariva.de/chart/?secu=6815

specializes in developing novel therapeutics for unmet medical needs and licensing those products to other pharmaceutical companies for commercialization. By utilizing a unique in-source model and focusing on integrated therapies, POZEN has successfully developed and obtained FDA approval of two self-invented products. Funded by these milestones/royalty streams, POZEN has created a portfolio of cost-effective, evidence-based integrated aspirin therapies designed to enable the full power of aspirin by reducing its GI damage. http://www.ariva.de/news/...eports-First-Quarter-2015-Results-5361986